Will Xeris Biopharma (XERS) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 11/01/21
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitBusiness Wire • 09/17/21
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaBusiness Wire • 09/14/21
Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/07/21
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)Business Wire • 09/01/21
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge BiopharmaBusiness Wire • 08/30/21
Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe HypoglycemiaBusiness Wire • 08/23/21
Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®Business Wire • 08/13/21
Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of HypothyroidismBusiness Wire • 08/11/21
Xeris Pharmaceuticals (XERS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/21
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent HighlightsBusiness Wire • 08/05/21
Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in IssueBusiness Wire • 07/29/21
Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021Business Wire • 07/29/21
Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial SuccessBusiness Wire • 07/28/21
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in EuropeBusiness Wire • 07/19/21